“Heading into 1Q25, we also believe BPMC could be seen as an attractive target for strategic partnerships, which could boost shares,” JP Morgan writes. With Ayvakit’s launch being a major focus for ...

The company’s lead gene therapy product, 4D-150, is showing potential in revolutionizing ... with effective inflammation management and high patient adherence to steroid prophylaxis. The vector ...

Archived copies of the webcasts will be available for up to one year by visiting the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.